Elizabeth A Eisenhauer
Overview
Explore the profile of Elizabeth A Eisenhauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1795
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gyawali B, Eisenhauer E, van der Graaf W, Booth C, Cherny N, Goodman A, et al.
Lancet Oncol
. 2025 Feb;
26(2):e80-e89.
PMID: 39914429
Common Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of randomised, controlled, phase...
2.
Alghamdi S, Ahimsadasan N, Kong W, Brundage M, Eisenhauer E, Parker C, et al.
Curr Oncol
. 2024 Oct;
31(10):6073-6084.
PMID: 39451757
(1) Background: Comprehensive and timely lung cancer (LC) staging is essential for prognosis and management. The Lung Diagnostic Assessment Program (LDAP) in Southeastern (SE) Ontario aims to provide rapid, guideline-concordant...
3.
Wilson B, Eisenhauer E, Booth C
JAMA
. 2024 May;
331(24):2081-2083.
PMID: 38767591
No abstract available.
4.
Booth C, Eisenhauer E, Gyawali B, Tannock I
J Clin Oncol
. 2024 Jan;
42(8):974-975.
PMID: 38290091
No abstract available.
5.
Booth C, Eisenhauer E, Gyawali B, Tannock I
J Clin Oncol
. 2023 Sep;
41(32):4968-4972.
PMID: 37733981
No abstract available.
6.
Booth C, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, et al.
Lancet Oncol
. 2023 Jul;
24(8):833-835.
PMID: 37467768
No abstract available.
7.
Brundage M, Booth C, Eisenhauer E, Galica J, Kankesan J, Karim S, et al.
J Natl Cancer Inst
. 2023 Jul;
115(12):1526-1534.
PMID: 37458509
Background: Cancer patients' attitudes toward progression-free survival (PFS) gains offered by treatment are not well understood, particularly in the absence of overall survival (OS) gains. The objectives were to describe...
8.
Alghamdi S, Kong W, Brundage M, Eisenhauer E, Parker C, Digby G
Curr Oncol
. 2023 May;
30(5):4880-4896.
PMID: 37232826
Introduction: Regional variability in lung cancer (LC) outcomes exists across Canada, including in the province of Ontario. The Lung Diagnostic Assessment Program (LDAP) in southeastern (SE) Ontario is a rapid-assessment...
9.
Saesen R, Van Hemelrijck M, Bogaerts J, Booth C, Cornelissen J, Dekker A, et al.
Eur J Cancer
. 2023 Apr;
186:52-61.
PMID: 37030077
The emergence of the precision medicine paradigm in oncology has led to increasing interest in the integration of real-world data (RWD) into cancer clinical research. As sources of real-world evidence...
10.
Mullin M, Shellenberger J, Whitehead M, Brundage M, Eisenhauer E, Lougheed M, et al.
Curr Oncol
. 2022 Dec;
29(12):9640-9659.
PMID: 36547171
: Lung cancer (LC) is the leading cause of cancer-related mortality. In Ontario, Canada, there are significant survival differences for patients with newly diagnosed LC across the 14 provincial regions....